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Adult Circulatory Support

National Landscape of Hospitalizations in Patients with
Left Ventricular Assist Device. Insights from the National
Readmission Database 2010–2015
ALEJANDRO LEMOR *,†, ALEXANDER MICHAELS*, WALEED AL-DARZI*, GABRIEL A. HERNANDEZ‡, YOUSSEF NASR*, PEDRO VILLABLANCA*,
VANESSA BLUMER §, CRISTINA TITA*, CELESTE T. WILLIAMS*, YELENA SELEKTOR*, DAVID E. LANFEAR*, JOANN Lindenfeld¶,
AND JENNIFER COWGER*

The number of patients with left ventricular assist devices
(LVAD) has increased over the years and it is important to
identify the etiologies for hospital admission, as well as the
costs, length of stay and in-hospital complications in this patient group. Using the National Readmission Database from
2010 to 2015, we identified patients with a history of LVAD
placement using International Classification of Diseases,
Ninth Revision, Clinical Modification (ICD-9-CM) code
V43.21. We aimed to identify the etiologies for hospital admission, patient characteristics, and in-hospital outcomes. We
identified a total of 15,996 patients with an LVAD, the mean
age was 58 years and 76% were males. The most common
cause of hospital readmission after LVAD was heart failure
(HF, 13%), followed by gastrointestinal (GI) bleed (11.8%),
device complication (11.5%), and ventricular tachycardia/fibrillation (4.2%). The median length of stay was 6 days (3–11
days) and the median hospital costs was $12,723 USD. The
in-hospital mortality was 3.9%, blood transfusion was required in 26.8% of patients, 20.5% had acute kidney injury,
2.8% required hemodialysis, and 6.2% of patients underwent
heart transplantation. Interestingly, the most common cause
of readmission was the same as the diagnosis for the preceding admission. One in every four LVAD patients experiences
a readmission within 30 days of a prior admission, most commonly due to HF and GI bleeding. Interventions to reduce HF
readmissions, such as speed optimization, may be one means
of improving LVAD outcomes and resource utilization.

The use of durable left ventricular assist devices (LVAD) for

the management of end-stage heart failure (HF) has increased
significantly over the past decade. Based on data from the 2019
Interagency Registry for Mechanically Assisted Circulatory
Support (INTERMACS), over 25,000 patients have received durable mechanical circulatory support in the United States1 and
rates of 30-day (now ~4%) and 1-year mortality (now ~17%)
have declined over time.2 Despite these gains, resource utilization after LVAD implant remains high. Only one in five LVAD
patients do not have a readmission within 12 months of LVAD
implant, dropping to 7% of patients by 36 months.3
Patients on LVAD support are prone to bleeding complications, neurologic events, right HF, infection and device complications.1 Aside from the incremental morbidity suffered by
individuals from these adverse events, readmissions contribute
to higher healthcare costs along with a decrease in patient
quality of life.2,4,5 While improved survival is critically important for patients with end-state HF, therapeutic “success” on
LVAD support requires consideration of morbidity and readmission burdens. Identification of adverse events with the highest frequency and/or with the highest associated readmission
costs can also help the field focus on technological advancements that are imperative for cost effectiveness.
Using a large national database, we aimed to 1) better scrutinize the hospital readmission burden in patients on LVAD support and 2) to characterize the associated costs associated with
hospital admissions in these patient population.

Key Words: LVAD, ventricular assist device, hospitalizations,
resource utilization
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Methods
Data Source
The study cohort was derived from the National Readmission
Database (NRD), a publicly available database of all-payer hospital inpatient stays developed by the Agency for Healthcare
Research and Quality as part of the Healthcare Cost and Utilization Project. The study included the NRD databases from
January 2010 to August 2015. The NRD was constructed from
22 states with reliable, verified patient linkage numbers in the
State Inpatient Databases that could be used to track the patient across hospitals within a state, while adhering to strict privacy guidelines. The NRD database includes approximately 14
million patients and around 2,000 hospitals per year. National
estimates are obtained using sampling weights provided. This
study was deemed exempt by the Institutional Review Board
as the NRD is a publicly available database that contains deidentified patient information.
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Study Cohort
Patients comprising the LVAD cohort of study were identified
in the NRD using the International Classification of Diseases,
Ninth Edition, Clinical Modification (ICD-9-CM) diagnostic
code V43.21 (“organ or tissue replaced by heart assist device”).
This ICD-9 code does not allow one to identify the index admission for LVAD implant; it only identifies patients with a durable LVAD during the period of study. For example, a patient
may have been implanted in 2007 or 2009. For the purposes of
this analysis, an LVAD admission had to occur between 2010
and 2015 and was defined as the primary admission herein
for the readmission analyses. Admissions after the primary admission were tracked as “readmissions.” In the NRD, patients
are assigned a unique identifier, which allows each LVAD patient to be tracked (the variable named “NRD_visitlink”) across
admissions. We determined the time between the first admission captured in the NRD and subsequent readmission(s) by
using the variable “NRD_daystoevent,” calculating the difference between that variable and the length of stay (LOS). A detailed explanation of all the variables in the NRD is available
online (https://www.hcup-us.ahrq.gov/nrdoverview.jsp).
All hospital admissions in the NRD containing the V43.21
code for the period of study were included in the analyses.
Subsequently, the five most common etiologies for hospital admission were analyzed separately. We considered the primary
admission the first hospital stay of the year in patients with the
ICD-9 code V43.21; hereafter, any admission within 30 days
of discharge following this primary admission was considered
the readmission. Supplemental Table 2 (Supplemental Digital
Content 1, http://links.lww.com/ASAIO/A482) included the
ICD-9 codes used to identify the top 5 etiologies for hospital
admission in the LVAD cohort. To verify that the ICD-9-CM
diagnostic code V43.21 was reflective of patients on active
LVAD support, and not just those who at any time were supported with an LVAD, we studied patients (n = 985) with an
LVAD that underwent heart transplantation or LVAD removal.
We found that those patients with subsequent admissions after
LVAD removal no longer had the V43.21 ICD-9 code assigned.
Based on the NRD suggested exclusion criteria,6 we excluded
records of patients younger than 18 years of age (n = 86), those
admitted during the month of December (for the years 2011 to
2014, and September for 2015) (n = 1,793), same day admission-transfers (n = 1,292), out of state patients (n = 3,251), and
patients who did not have mortality data (n = 15).
Patient and Hospital Characteristics
Baseline patient characteristics such as age, gender, primary
expected payer, relevant comorbidities were collected using already defined variables in the NRD database or by using ICD9
codes (see Table 1, Supplemental Digital Content 1, http://links.
lww.com/ASAIO/A482). The severity of comorbid conditions was
defined using a validated Deyo modification of Charlson Comorbidity Index.7,8 Other characteristics such as teaching status of the
hospital, median household income, insurance status, elective
admission status, and discharge disposition were also included.
Study Outcomes
Study outcomes were divided as resource utilization and
clinical outcomes. Resource utilization comprised LOS,

median hospital costs per patient, total hospital costs, use
of echocardiogram (transthoracic or transesophageal), right
heart catheterization, mechanical ventilation, repair or replacement of LVAD, palliative care consultation, and blood
transfusion. Clinical outcomes included in-hospital mortality,
30-day all-cause readmission (both unplanned and planned
readmissions were included), acute kidney injury (AKI), AKI
requiring dialysis, heart transplantation, ischemic stroke,
hemorrhagic stroke, bleeding, device complication, HF, and
discharge to a nursing home or skilled facility. The ICD-9-CM
codes used to identify and define these variables are listed in
Tables 1 and 2 (Supplemental Digital Content 1, http://links.
lww.com/ASAIO/A482).
Results
A total of 15,996 patients on LVAD support were identified
as having at least one admission during the period of study.
Table 1 outlines the clinical characteristics and demographics
of the cohort. The mean age was 58 years (SD, 13.3), 51.8%
of patients were older than 60 years, and only 24% were female. The majority of patients were admitted to large teaching
hospitals and 57.9% had Medicare as their primary insurance.
Clinical Outcomes and Resource Utilization
of the Entire Readmission Cohort
Between 2010 and 2013, there was a decline in readmission frequency in patients on LVAD support, from 28% to 23%
(Figure 1). After 2013, readmission rates demonstrated an increase. This trend mirrors the trend in increased LVAD utilization across the United States.
The most common diagnoses for hospital readmission
in patients with LVAD implant included acute HF (2,079
[13.0%]), gastrointestinal (GI) bleeding (1,891 [11.8%]), device complications (1,837 patients [11.5%]), ventricular tachycardia (VT) (666 [4.2%]), and acute cerebrovascular disease
(530 [3.3%]). The complete list of hospitalization etiologies
can be found in Supplemental Table 3 (Supplemental Digital Content 1, http://links.lww.com/ASAIO/A482). At 30 days
from the primary admission, the readmission rate was 24.9%.
Interestingly, the top reasons for 30-day readmission were
the same as the primary admission diagnosis after ventricular
assist devices (VAD) stay (Figure 2).
The in-hospital mortality at primary admission within the
LVAD sample was 3.9%. One in every five patients developed AKI, 6.2% underwent heart transplantation, and 5.4% of
patients were discharged to nursing home or skilled nursing
facility. The overall median LOS was 6 days (interquartile range
[IQR]: 3–11), median hospital costs per patient were $12,723
(Figure 3), and the total hospital costs for the entire cohort was
$510 million.
Acute Heart Failure
Heart failure was the most common reason for primary hospitalization in the LVAD cohort, affecting 13%. The mean age
was 56.5 (SD, 12.7) years old and 25% were female. Compared with the overall LVAD cohort, patients with an admission for heart failure were more often obese (23.4%), with high
frequencies of atrial fibrillation, advanced chronic kidney disease (CKD) and/or end stage renal disease (ESRD). The median
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Table 1.  Baseline Patient and Hospital Characteristics by Primary Admission Diagnosis
Overall

Acute Heart
Failure

No. of patients (% of
15,996 (100%) 2,079 (13.0%)
overall population)
Age, mean (SD)
58.0 (13.3)
56.5 (12.7)
 <40 years old
10.4%
11.6%
 40–49 years old
12.9%
13.0%
 50–59 years old
24.9%
27.6%
 60–69 years old
32.2%
35.3%
 70–79 years old
17.6%
11.5%
 
≥80 years old
2.0%
1.0%
Female
24.0%
25.0%
Comorbidities
 Hypertension
56.0%
53.9%
 Dyslipidemia
40.9%
39.3%
 Diabetes
38.1%
40.0%
 Diabetes with insulin use
8.9%
8.7%
 Prior MI
18.8%
16.1%
 Prior PCI
10.2%
9.4%
 Previous CABG
14.2%
14.9%
 Prior pacemaker
2.2%
3.1%
 Prior ICD
17.5%
15.3%
 Atrial fibrillation
36.1%
40.3%
 COPD
14.3%
12.0%
 Advanced CKD
17.8%
22.7%
 ESRD
2.0%
2.5%
 Carotid artery disease
0.8%
0.4%
 Prior CVA
13.3%
10.3%
 Peripheral vascular
6.9%
6.6%
disease
 Obese
17.0%
23.4%
 Anemia
24.6%
31.4%
 Liver disease
2.2%
2.8%
 Alcohol abuse
1.7%
2.5%
 Drug abuse
1.9%
2.2%
 Coagulopathy
10.7%
16.4%
 Hypothyroidism
16.7%
18.2%
 Valve disease
11.4%
0.3%
 Chronic antiplatelet/
21.7%
21.5%
antithrombotic use
 Smoking history
28.0%
23.2%
Other characteristics
 Hospital bedsize
  
Small
1.3%
0.9%
  
Medium
6.4%
6.4%
  
Large
92.3%
92.7%
 Teaching hospital
95.8%
96.1%
 Elective admission
19.5%
23.2%
 Primary payer
  
Medicare
57.9%
53.8%
  
Medicaid
10.6%
11.6%
  
Private insurance
28.4%
30.8%
  
Self-pay/other
3.0%
3.8%
 Median household
income
  
0–25th percentile
28.7%
30.9%
  
26th–50th percentile
25.0%
25.5%
  
51st–75th percentile
24.1%
23.0%
  
76th–100th percentile
22.2%
20.7%
 Publication year
  
2010
6.8%
8.3%
  
2011
11.0%
13.5%
  
2012
15.0%
14.5%
  
2013
20.1%
19.3%
  
2014
23.7%
22.1%
  
2015*
23.4%
22.3%

Gastrointestinal
Bleeding

Device
Complication

Ventricular
Tachycardia

Acute
Cerebrovascular Disease

1,891 (11.8%)

1,837 (11.5%)

666 (4.2%)

530 (3.3%)

63.0 (10.5)
2.7%
7.2%
21.4%
39.7%
26.9%
2.2%
23.8%

54.7 (14.4)
15.4%
17.3%
26.0%
25.3%
14.8%
1.1%
27.1%

58.6 (12.8)
8.4%
14.1%
25.2%
29.5%
21.5%
1.3%
14.5%

58.9 (11.8)
8.0%
11.5%
25.4%
37.7%
16.5%
9.7%
20.4%

63.6%
47.7%
40.1%
8.1%
21.8%
9.7%
21.9%
2.9%
17.4%
41.5%
19.9%
21.8%
0.6%
0.9%
12.2%
7.7%

52.0%
37.5%
38.8%
5.2%
15.4%
6.4%
8.6%
1.9%
17.3%
31.9%
11.3%
18.8%
0.3%
0.3%
12.0%
7.9%

57.8%
43.4%
35.8%
10.5%
22.5%
12.3%
13.3%
1.4%
30.1%
48.6%
15.9%
17.3%
2.7%
0.5%
10.1%
5.4%

64.6%
44.7%
37.9%
5.7%
17.0%
12.7%
14.1%
5.1%
17.9%
38.5%
13.7%
16.8%
2.4%
3.6%
14.4%
6.0%

11.7%
20.2%
3.7%
1.1%
1.2%
7.0%
18.1%
17.0%
20.8%

21.9%
26.6%
1.6%
1.7%
3.5%
12.7%
15.9%
11.5%
18.1%

16.9%
20.5%
0.2%
0.2%
1.7%
3.1%
14.7%
0.0%
27.3%

11.7%
25.9%
1.1%
1.0%
1.0%
10.6%
18.5%
15.0%
20.0%

33.2%

26.0%

31.6%

24.3%

1.0%
5.5%
93.5%
97.3%
15.3%

0.2%
7.5%
92.3%
97.1%
15.6%

0.9%
4.7%
94.3%
96.6%
10.6%

2.5%
5.3%
92.2%
96.1%
7.6%

64.5%
7.0%
25.3%
3.3%

57.4%
15.6%
24.3%
2.7%

60.6%
8.3%
29.1%
2.0%

58.4%
8.1%
32.7%
0.8%

30.0%
25.1%
22.2%
22.7%

29.8%
25.7%
25.5%
19.0%

29.5%
20.3%
26.4%
23.4%

26.1%
27.2%
26.9%
19.8%

5.0%
8.5%
13.0%
23.0%
26.0%
24.5%

6.6%
9.4%
11.6%
21.2%
22.5%
28.7%

7.6%
9.9%
13.7%
22.1%
25.4%
21.3%

8.7%
9.5%
11.5%
21.8%
23.1%
25.5%

*From January to September 2015.
CABG, coronary artery bypass graft; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular
accident; ESRD, end stage renal disease; ICD, implantable cardioverter-defibrillator; MI, myocardial infarction, PCI, percutaneous coronary
intervention.
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Figure 1. Primary admission diagnosis by year in patients with LVAD. The number of hospitalizations in patients with LVAD has increased
from around 500 patients in 2010 to more than 1700 patients in 2015. Between 2010 and 2013, there was a decline in readmission frequency
in patients on LVAD support, from 28 to 23%; after 2013, readmission rates demonstrated an increase.

LOS was eight (4–14) days and hospital costs ($15,759) were
approximately $3,000 higher than that of the overall cohort.
While in-hospital mortality was lower (2.8%) than that of the
general LVAD cohort, the rate of heart transplantation was
highest at 19.2%. This group also had high requirements for
mechanical ventilation (7%) with the highest frequency of AKI
(30.8%). Finally, use of echocardiography (13.5%) was higher
than that of the general cohort of patients with LVAD and right
heart catheterizations (8.3%) occurred with the highest frequency in this group.

Gastrointestinal Bleeding
A total of 1,891 (11.8%) LVAD patients had a primary
hospital admission due to GI bleeding in the study period.
Patients in this group were older (63 years old) than the
general LVAD cohort, and more GI bleed patients had hypertension, chronic obstructive pulmonary disease, atrial
fibrillation, prior coronary artery bypass graft or percutaneous coronary intervention, hypothyroidism, advanced
CKD, and smoking history. There were fewer patients with
obesity and ESRD in those with GI bleeding. The median

Figure 2. Median hospital costs for each hospital admission in the LVAD cohort.
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Figure 3. Most common 30-day readmission causes by group. There were 15,996 patients in the total cohort. The first box shows the
indications for readmission in order of frequency. The second box shows the readmission rate at 30-day for the given primary readmission diagnosis. The final box breaks down the causes of readmission after first readmission. For example, acute heart failure was the most common
cause of primary admission. Of these, 22% were readmitted in 30 days and 29% were readmitted for another acute HF flair.

LOS was similar to the total cohort at 7 days (4–11) and
in-hospital mortality was the second lowest (1%) of the
complications. However, hospital costs ($14,346) were approximately $1,600 higher than average; 71.4% of patients
required a blood transfusion and 67% of patients had upper
endoscopy and/or colonoscopy was performed. The 30-day
readmission rate after a GI bleed was the highest for any
complication at 28.7%, and half of these patients were
admitted for a recurrent GI bleed.

Device Complication
A total of 1,837 hospitalizations occurred due to device
complications, representing 11.5% of all hospitalizations
in patients on an LVAD. Females and young patients were
more likely to experience device complications (Table 1).
Compared to the overall LVAD cohort, the median LOS
was longer (8 days [IQR: 4–15]), and complication burdens
were high: Almost 25% of patients had sepsis, 7.3% of patient required repair or replacement of the LVAD (compared

Copyright © American Society of Artificial Internal Organs. Unauthorized reproduction of this article is prohibited.
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with 0.9% of the general VAD readmission cohort), 18.1%
of patients required blood transfusions, 25% had AKI, and
2.1% had heart transplant. Compared with other complications, in-hospital mortality in patients admitted with a device
dysfunction was second highest at 3.8% and hospital costs
($17,490) were the highest.
Ventricular Tachycardia
Ventricular tachycardia was the admission diagnosis for
4.2% of patients (4.2%). Patients with VT were least likely
to be female and more likely to have had prior myocardial
infarction and/or revascularization (Table 1). An implantable cardioverter-defibrillator (ICD) was present in 30% of
patients and 6.8% of patients without a prior ICD underwent
ICD placement. Among patients admitted with VT, 8.9% underwent catheter ablation. The LOS (4 days [2–6]), hospital
costs ($8,534), and in-hospital mortality (0.5%) were lowest
in this cohort.
Acute Cerebrovascular Disease
While acute cerebrovascular disease had affected only 3.3%
of the overall cohort (530 patients), the complication was associated with the poor clinical outcomes and high costs. The
mean age was 59.9 years and 20.4% were females. More
patients had hypertension (64.6%) and carotid artery disease
(3.6%) when compared to the overall LVAD cohort. While the
mean LOS (6 days [2–12]) approximated that of the general
cohort, hospital costs were the second highest of the complications at $16,218, and complications including need for mechanical ventilation (26%), requirement for blood transfusions
(23.5%), and development of sepsis (10.4%) were high. Palliative care consultation was overall low in the study (2.5%
of the general population) but patients with acute cerebrovascular events triggered their services in 16.6%. Congruently, the
in-hospital mortality was the highest among the other cohorts
(30.8%), and 10.9% of patients were discharged to a nursing
home or skilled nursing facility compared with only 5% of the
general cohort.
Discussion
In this large national database study, we attempted to characterize the patient journey during LVAD support, including
the burden of readmissions, morbidities, and mortality. In
addition, we examined the morbidity impact of the most common causes for readmission and their associated costs. Our
findings are congruent with previous studies identifying acute
heart failure, bleeding, device complication, and arrhythmias
as the most common etiologies for hospital admission postLVAD.1,3,5,9–18 What is added to the literature is the finding that
subsequent re-admissions are most commonly for the same
reason as the primary admission. The complication of highest frequency in patients with LVAD was heart failure, leading to the highest total hospital costs at $99 million. While
GI bleeding is a low mortality complication, hospital costs are
not trivial and readmission rates are high, making it the third
most costly complication for the health system at $41 million.
Overall, while LVAD technology has improved with improved
survival, our composite results and utilization data suggest the

field has a long way to go before we can call LVAD support a
true “success.”
In this analysis, acute heart failure was the most common
indication for admission in patients on LVAD support, consistent with findings in previous studies.2,5,15,16,19 As a cohort,
this group of patients was the most costly in terms of absolute
health care dollars spent- accounting for $98.5 million. There
was also a drastically elevated rate of transplant in this group,
occurring in 19.2% of patients during that hospital admission
for heart failure. This is a finding that has not previously been
reported and we hypothesize that it reflects the development of
new or progressive right heart failure after LVAD implant. This
hypothesis is supported by the increased frequency of acute
renal injury, use of renal replacement therapy, and right heart
catheterization during their hospitalization. The re-admission
rate post discharge was 22.3% which was the lowest of the five
groups. This is at least in part attributed to the fact that nearly
one in five of these patients received a transplant. Despite this,
admission for acute heart failure in those surviving to discharge
approached 30%.
Gastrointestinal bleeding represented the second most common admission indication in our study which again is similar to
prior studies and consistent with reports from INTERMACS.1,3,15
What is added is that we found this to be the most common
diagnosis resulting in hospital re-admission and the strongest
predictor of recurrent GI bleeding. Unsurprisingly this group
utilized blood transfusions at a significantly higher rate than
the others (71.8% vs. 26.8% overall). Interestingly GI bleed
was associated with the second fewest comorbid acute conditions during hospitalization but the highest frequency of
re-admission (28.7%) with nearly half of those being due to
subsequent GI bleed.
Device complication represented the third most common
indication for hospital admission following LVAD.15,16 This is a
broad and heterogenous group that in our study included infection, driveline fracture, pump thrombosis, and failure along
with many others (Table 2). Device complication requiring readmission occurred in 11.5% of patients. This accounted for
15.9% of total costs, second only to heart failure as primary
cause of admission, with the highest per patient cost averaging
$17,490/hospitalization. Analysis identified this group as an
above average risk for re-admission as well with 26.6% presenting within 30 days for a subsequent admission with recurrent device complication being the primary reason in 37% of
patients returning (Figure 2). As a group these patients tended
to be younger, female, and have non-ischemic causes for their
heart failure.
Ventricular tachycardia occurred as the fourth most prevalent readmission diagnosis in this study affecting 4.4% of
patients and at an average hospitalization cost significantly
lower than all other top 5 diagnosis. Ventricular tachycardia
is well described in the post-LVAD population20,21 and has
been attributed to a multitude of factors including those directly related to the pump such as suction events and myocardial scar around the implant site. Additionally, physiologic
changes post-VAD have been described as potential etiologies
of early ventricular arrhythmias due to rapid shifts in myocardial electrolytes resulting in arrhythmophilic states as well as
more whole-body systemic electrolyte imbalances due to sudden improved renal function and kaliuresis.20 Short term these
arrhythmias are well tolerated by most VAD patients due to the
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Table 2.  Resource Utilization and Hospital Outcomes by Primary Admission Diagnosis
Primary Admission Diagnosis
Overall

Acute
Heart Failure

Gastrointestinal
Bleeding

Device
Complication

Ventricular
Tachycardia

Acute
Cerebrovascular Disease

8 (4–14)
98.5

7 (4–11)
41.2

8 (4–15)
81.4

4 (2–6)
13.9

6 (2–12)
20.0

13.5%
8.3%
0.1%
7.0%
6.5%
1.7%
9.1%

2.8%
1.3%
0.1%
0.3%
3.7%
1.1%
71.4%

14.7%
3.1%
7.3%
6.1%
24.9%
2.9%
18.1%

12.9%
1.1%
0.0%
3.0%
1.6%
1.5%
9.4%

10.7%
1.1%
0.4%
26.0%
10.4%
16.6%
23.5%

2.8%
22.3%
30.8%
2.7%
19.2%
0.4%
0.3%
5.0%

1.0%
28.7%
14.8%
0.3%
0.2%
0.3%
0.0%
4.2%

3.8%
26.6%
25.2%
1.0%
2.1%
2.8%
1.2%
5.4%

0.5%
23.2%
14.5%
0.8%
0.8%
0.2%
0.8%
4.5%

30.8%
22.8%
15.7%
1.2%
0.4%
56.2%
43.8%
10.9%

Resource utilization
 Length of stay, median (IQR)
6 (3–11)
 Median total hospital costs
510.0
(million US$)
 Echo/TEE
10.2%
 Right heart catheterization
3.1%
 Repair or replacement of VAD
0.9%
 Mechanical ventilation
6.2%
 Sepsis
10.7%
 Palliative care consultation
2.5%
 Blood transfusion
26.8%
Clinical outcomes
 In-hospital mortality
3.9%
 30-day readmission rate*
24.9%
 Acute kidney injury
20.5%
 AKI requiring dialysis
1.6%
 Heart transplantation
6.2%
 Ischemic stroke
2.9%
 Hemorrhagic stroke
1.3%
 Discharge to nursing home/facility
5.4%
*Patients that survived primary admission.
AKI, acute kidney injury; IQR, interquartile range.

continuous unloading of the left ventricle, however, over time
there is significant detrimental effect to the RV when left unchecked. Our data demonstrates this as 23.2% of patients who
presented with VT will have subsequent admission within 30
days with more than 20% of those presenting with acute HF
and acute renal injury in nearly 15%. The overall cost burden
is low for this group and likely reflects the relative tolerance
and hemodynamic stability as the rates of acute comorbidities
was lowest in this group and were the least likely to undergo
procedural intervention. This is largely attributed to the vast
majority of patients receiving LVAD already having intracardiac defibrillators in place.22 There has been increasing investigations into the practicality and durability of VT ablation both
intraoperatively and postoperative for reducing long-term arrhythmia burden.21,23,24
Finally, acute cerebrovascular events are the final major
readmission diagnosis that this data set identified. Although
this occurs in a small group of patients, 3.3% of the study
population, it has the most profound effect on morbidity and
mortality.3 Baseline characteristics also demonstrated a significant preexisting cerebrovascular disease burden in this
subgroup with 14.4% having prior cerebrovascular accident
(CVA) compared to a 12.5% for the remaining four groups.
Nearly one in three patients suffered in-hospital mortality and
a quarter required mechanical ventilation. The median cost
of acute CVA was exceeded only by device complications
and is a reflection of the acuity of illness this cohort represents with high intensive care usage and significant comorbid
conditions including high rates of AKI, transfusions, and importantly sepsis. Ischemic stroke represented the majority of
acute CVA in our study at 56.2% vs. 43.8% hemorrhagic.
With newer technology and improved device design, rates
of complications can potentially be reduced; as seen in MOMENTUM 3 trial, which showed lower rates of stoke among
patients with centrifugal-flow pump when compared with

axial-flow pumps (10.1% vs. 19.2%, P = 0.02).25 There is a
preponderance of evidence in the literature demonstrating a
high correlation within the LVAD population for cerebrovascular accidents to be preceded by bacteremia or other device
related infection.26–29 Further chronic changes suffered by
patients with long-standing heart failure have been shown to
cause changes to the blood brain barrier, cerebral autoregulation, and histological changes the central nervous system
arterioles.30–32
Limitations
There are several limitations to the current study due to
the administrative nature of the database. It is not possible
to identify the type of durable LVAD implanted and precisely
when the operation occurred, limiting our ability to examine
outcomes and costs by brand. Further, it is not possible to distinguish some in-hospital complications from comorbidities
with this administrative database. This is a critical limitation
for stroke outcomes. The mortality data does not distinguish
between cardiac and non-cardiac causes of death and this
analysis is limited to in-hospital outcomes. The NRD data are
based on ICD-9-CM codes and there is a possibility of coding
error as well as under coding certain diagnoses. Finally, the
lack of information about laboratory results, medications, and
diagnostic imaging results is also a limitation. Despite these
limitations, by using the largest national sample of hospital
admissions in the United States, this study showed important
findings among patients with an LVAD and their resource utilization and hospital outcomes.
Conclusion
In conclusion, the overall frequency of admissions in LVAD
patients remains elevated and long-term cost burdens continue
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to be significant. As the field advances, it will be critical to
capture outcomes that extend beyond survival so that a clearer
understanding of the patient journey is resulted. A focus on reducing health care dollars through improved technology with
low readmission and morbidity burdens should be a priority
for the field of mechanical circulatory support.
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